Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Умеренные когнитивные расстройства: роль Пронорана в их коррекции
Умеренные когнитивные расстройства: роль Пронорана в их коррекции
Пилипович А.А. Умеренные когнитивные расстройства: роль Пронорана в их коррекции. Consilium Medicum. 2017; 19 (2.3. Неврология и Ревматология): 38–42. DOI: 10.26442/2075-1753_19.2.3.38-42
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Статья посвящена проблеме умеренных когнитивных нарушений, их распространенности, этиологии, особенностям патогенеза, принципам терапии и профилактики развития деменции. Приведены данные по эффективности терапии когнитивных расстройств агонистом дофаминовых рецепторов – пирибедилом (Проноран®).
Ключевые слова: умеренные когнитивные расстройства, профилактика деменции, терапия когнитивных расстройств, пирибедил, Проноран.
Key words: moderate cognitive disorders, prophylaxis of dementia, therapy of cognitive disorders, piribedil, Pronoran.
Ключевые слова: умеренные когнитивные расстройства, профилактика деменции, терапия когнитивных расстройств, пирибедил, Проноран.
________________________________________________
Key words: moderate cognitive disorders, prophylaxis of dementia, therapy of cognitive disorders, piribedil, Pronoran.
Полный текст
Список литературы
1. Левин О.С. Диагностика и лечение деменций в клинической практике. М.: МЕДпресс-информ, 2010. / Levin O.S. Diagnostika i lechenie dementsii v klinicheskoi praktike. M.: MEDpress-inform, 2010. [in Russian]
2. Smith G, Chandler M, Locke DE et al. Behavioral Interventions to Prevent or Delay Dementia: Protocol for a Randomized Comparative Effectiveness Study. JMIR Res Protoc 2017; 6 (11): e223.
3. Пилипович А.А. Умеренные когнитивные расстройства. Consilium Medicum. 2016; 2: 44–9. / Pilipovich A.A. Moderate cognitive disorders. Consilium Medicum. 2016; 18 (2): 44–9.
4. Захаров В.В. Современные подходы к терапии когнитивных нарушений, не достигающих выраженности деменции. Эффективная фармакотерапия. Неврология и психиатрия. 2013; 1: 56–62. / Zakharov V.V. Sovremennye podkhody k terapii kognitivnykh narushenii, ne dostigaiushchikh vyrazhennosti dementsii. Effektivnaia farmakoterapiia. Nevrologiia i psikhiatriia. 2013; 1: 56–62. [in Russian]
5. Яхно Н.Н., Захаров В.В., Локшина А.Б. и др. Деменции: руководство для врачей. 4-е изд. М.: МЕДпресс-информ, 2013. / Yakhno N.N., Zakharov V.V., Lokshina A.B. i dr. Dementsii: rukovodstvo dlia vrachei. 4-e izd. M.: MEDpress-inform, 2013. [in Russian]
6. Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7 (3): 270–9.
7. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia – meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009; 119 (4): 252–65.
8. Cooper C, Li R, Lyketsos C, Livingston G. Treatment for mild cognitive impairment: systematic review. Br J Psychiatry 2013; 203 (3): 255–64.
9. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011; 10 (9): 819–28.
10. Smith GE, Bondi MW. Mild Cognitive Impairment and Dementia: Definitions, Diagnosis, and Treatment. Oxford; New York: Oxford University Press, 2013.
11. Volkow N, Wang G, Fowler J et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol 1998; 1: 143–7.
12. Halliday G, Barker R, Rowe D. Non-dopamine lesions in Parkinson’s disease. Oxford University Press, 2011; p. 314.
13. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 2001; 9: 1517–9.
14. Calzi F, Bellasio R, Guiso G et al. Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. Eur J Pharmacol 1997; 5 (338): 185–90.
15. Захаров В.В., Локшина А.Б. Применение препарата Проноран (пирибедил) при легких когнитивных расстройствах у пожилых больных с дисциркуляторной энцефалопатией. Неврол. журн. 2004; 2: 30–5. / Zakharov V.V., Lokshina A.B. Primenenie preparata Pronoran (piribedil) pri legkikh kognitivnykh rasstroistvakh u pozhilykh bol'nykh s distsirkuliatornoi entsefalopatiei. Nevrol. zhurn. 2004; 2: 30–5. [in Russian]
16. Brocco M, Dekeyne A, Papp M, Millan MJ. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav Pharmacol 2006; 17 (7): 559–72.
17. Schrag A, Sauerbier A, Chaudhuri KR. New clinical trials for nonmotor manifestations of Parkinson’s disease. Mov Disord. 2015; 30 (11): 1490–504.
18. Thobois S, Lhommée E, Klinger H et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013; 5 (136): 1568–77.
19. Kahvecioglu U, Özkaynak S, Zadikoglu A et al. Efficacy of piribedil on age – related cognitive decline. Medical J Akdeniz University Cilt XII, Sayi 1–3. 1995.
20. Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil. J Neurol 1992; 239 (Suppl. 1): 13–6.
21. Пилипович А.А. Биоэлектрическая активность головного мозга у пациентов с болезнью Паркинсона. Врач. 2012; 4: 107–12. / Pilipovich A.A. Bioelektricheskaia aktivnost' golovnogo mozga u patsientov s bolezn'iu Parkinsona. Vrach. 2012; 4: 107–12. [in Russian]
22. Corradino et al. Trivastal retard 50 in everyday medical practice. Its value in the treatment of dizziness, tinnitus and memory disorders. Trib Med 1988; 3: 39–42.
23. Corbe C, Arnaud F, Brault Y et al. Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects. J Neurol 1992; 239: 22–7.
24. Lassare P, Coppolani T. National multicenter trial in 6000 patients of trivastal retard, 1 tablet per day, in treatment of cerebral insufficiency. Vie Med 1980; 61: 39–50.
25. Пилипович А.А. Влияние Пронорана на депрессивные расстройства при болезни Паркинсона. Consilium Mediсum. 2012; 9: 62–5. / Pilipovich A.A. Vliianie Pronorana na depressivnye rasstroistva pri bolezni Parkinsona. Consilium Medicum. 2012; 9: 62–5. [in Russian]
26. Федорова Н.В., Ким И.П. Лечение болезни Паркинсона. Журн. неврологии и психиатрии. 2002; 2: 68–75. / Fedorova N.V., Kim I.P. Lechenie bolezni Parkinsona. Zhurn. nevrologii i psikhiatrii. 2002; 2: 68–75. [in Russian]
27. Ziegler M, Rondot P. Activity of piribedil in Parkinson’s diseas: a multicenter study. Presse Med 1999; 28: 1414–8.
28. Артемьев Д.В., Захаров В.В., Левин О.С. и др. Старение и нейродегенеративные расстройства: когнитивные и двигательные нарушения в пожилом возрасте. М., 2005. / Artem'ev D.V., Zakharov V.V., Levin O.S. i dr. Starenie i neirodegenerativnye rasstroistva: kognitivnye i dvigatel'nye narusheniia v pozhilom vozraste. M., 2005. [in Russian]
29. Захаров В.В. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). Неврол. журн. 2006; 11: 27–32. / Zakharov V.V. Vserossiiskaia programma issledovanii epidemiologii i terapii kognitivnykh rasstroistv v pozhilom vozraste (“Prometei”). Nevrol. zhurn. 2006; 11: 27–32. [in Russian]
30. Яхно Н.Н., Захаров В.В. Срачунская Е.Я. и др. Лечение недементных когнитивных нарушений у пациентов с артериальной гипертензией и церебральным атеросклерозом. (По результатам российского мультицентрового исследования ФУЭТЕ). Неврол. журн. 2012; 4: 49–55. / Yakhno N.N., Zakharov V.V. Srachunskaia E.Ya. i dr. Lechenie nedementnykh kognitivnykh narushenii u patsientov s arterial'noi gipertenziei i tserebral'nym aterosklerozom. (Po rezul'tatam rossiiskogo mul'titsentrovogo issledovaniia FUETE). Nevrol. zhurn. 2012; 4: 49–55. [in Russian]
31. Левин О.С., Голубева Л.В. Гетерогенность умеренного когнитивного расстройства: диагностические и терапевтические аспекты. Consilium Medicum. 2006; 8 (2): 106–12. / Levin O.S., Golubeva L.V. Geterogennost' umerennogo kognitivnogo rasstroistva: diagnosticheskie i terapevticheskie aspekty. Consilium Medicum. 2006; 8 (2): 106–12. [in Russian]
32. Ганькина О.А. и др. Влияние пирибедила на умеренные когнитивные нарушения при дисциркуляторной энцефалопатии. Журн. неврологии и психиатрии им. С.С.Корсакова. (Прил. Геронтология). 2014; 6 (2): 61–6. / Gankina O.A. i dr. Vliianie piribedila na umerennye kognitivnye narusheniia pri distsirkuliatornoi entsefalopatii. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. (Pril. Gerontologiia). 2014; 6 (2): 61–6. [in Russian]
2. Smith G, Chandler M, Locke DE et al. Behavioral Interventions to Prevent or Delay Dementia: Protocol for a Randomized Comparative Effectiveness Study. JMIR Res Protoc 2017; 6 (11): e223.
3. Pilipovich A.A. Moderate cognitive disorders. Consilium Medicum. 2016; 18 (2): 44–9.
4. Zakharov V.V. Sovremennye podkhody k terapii kognitivnykh narushenii, ne dostigaiushchikh vyrazhennosti dementsii. Effektivnaia farmakoterapiia. Nevrologiia i psikhiatriia. 2013; 1: 56–62. [in Russian]
5. Yakhno N.N., Zakharov V.V., Lokshina A.B. i dr. Dementsii: rukovodstvo dlia vrachei. 4-e izd. M.: MEDpress-inform, 2013. [in Russian]
6. Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7 (3): 270–9.
7. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia – meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009; 119 (4): 252–65.
8. Cooper C, Li R, Lyketsos C, Livingston G. Treatment for mild cognitive impairment: systematic review. Br J Psychiatry 2013; 203 (3): 255–64.
9. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011; 10 (9): 819–28.
10. Smith GE, Bondi MW. Mild Cognitive Impairment and Dementia: Definitions, Diagnosis, and Treatment. Oxford; New York: Oxford University Press, 2013.
11. Volkow N, Wang G, Fowler J et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol 1998; 1: 143–7.
12. Halliday G, Barker R, Rowe D. Non-dopamine lesions in Parkinson’s disease. Oxford University Press, 2011; p. 314.
13. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 2001; 9: 1517–9.
14. Calzi F, Bellasio R, Guiso G et al. Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. Eur J Pharmacol 1997; 5 (338): 185–90.
15. Zakharov V.V., Lokshina A.B. Primenenie preparata Pronoran (piribedil) pri legkikh kognitivnykh rasstroistvakh u pozhilykh bol'nykh s distsirkuliatornoi entsefalopatiei. Nevrol. zhurn. 2004; 2: 30–5. [in Russian]
16. Brocco M, Dekeyne A, Papp M, Millan MJ. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav Pharmacol 2006; 17 (7): 559–72.
17. Schrag A, Sauerbier A, Chaudhuri KR. New clinical trials for nonmotor manifestations of Parkinson’s disease. Mov Disord. 2015; 30 (11): 1490–504.
18. Thobois S, Lhommée E, Klinger H et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013; 5 (136): 1568–77.
19. Kahvecioglu U, Özkaynak S, Zadikoglu A et al. Efficacy of piribedil on age – related cognitive decline. Medical J Akdeniz University Cilt XII, Sayi 1–3. 1995.
20. Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil. J Neurol 1992; 239 (Suppl. 1): 13–6.
21. Pilipovich A.A. Bioelektricheskaia aktivnost' golovnogo mozga u patsientov s bolezn'iu Parkinsona. Vrach. 2012; 4: 107–12. [in Russian]
22. Corradino et al. Trivastal retard 50 in everyday medical practice. Its value in the treatment of dizziness, tinnitus and memory disorders. Trib Med 1988; 3: 39–42.
23. Corbe C, Arnaud F, Brault Y et al. Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects. J Neurol 1992; 239: 22–7.
24. Lassare P, Coppolani T. National multicenter trial in 6000 patients of trivastal retard, 1 tablet per day, in treatment of cerebral insufficiency. Vie Med 1980; 61: 39–50.
25. Pilipovich A.A. Vliianie Pronorana na depressivnye rasstroistva pri bolezni Parkinsona. Consilium Medicum. 2012; 9: 62–5. [in Russian]
26. Fedorova N.V., Kim I.P. Lechenie bolezni Parkinsona. Zhurn. nevrologii i psikhiatrii. 2002; 2: 68–75. [in Russian]
27. Ziegler M, Rondot P. Activity of piribedil in Parkinson’s diseas: a multicenter study. Presse Med 1999; 28: 1414–8.
28. Artem'ev D.V., Zakharov V.V., Levin O.S. i dr. Starenie i neirodegenerativnye rasstroistva: kognitivnye i dvigatel'nye narusheniia v pozhilom vozraste. M., 2005. [in Russian]
29. Zakharov V.V. Vserossiiskaia programma issledovanii epidemiologii i terapii kognitivnykh rasstroistv v pozhilom vozraste (“Prometei”). Nevrol. zhurn. 2006; 11: 27–32. [in Russian]
30. Yakhno N.N., Zakharov V.V. Srachunskaia E.Ya. i dr. Lechenie nedementnykh kognitivnykh narushenii u patsientov s arterial'noi gipertenziei i tserebral'nym aterosklerozom. (Po rezul'tatam rossiiskogo mul'titsentrovogo issledovaniia FUETE). Nevrol. zhurn. 2012; 4: 49–55. [in Russian]
31. Levin O.S., Golubeva L.V. Geterogennost' umerennogo kognitivnogo rasstroistva: diagnosticheskie i terapevticheskie aspekty. Consilium Medicum. 2006; 8 (2): 106–12. [in Russian]
32. Gankina O.A. i dr. Vliianie piribedila na umerennye kognitivnye narusheniia pri distsirkuliatornoi entsefalopatii. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. (Pril. Gerontologiia). 2014; 6 (2): 61–6. [in Russian]
2. Smith G, Chandler M, Locke DE et al. Behavioral Interventions to Prevent or Delay Dementia: Protocol for a Randomized Comparative Effectiveness Study. JMIR Res Protoc 2017; 6 (11): e223.
3. Пилипович А.А. Умеренные когнитивные расстройства. Consilium Medicum. 2016; 2: 44–9. / Pilipovich A.A. Moderate cognitive disorders. Consilium Medicum. 2016; 18 (2): 44–9.
4. Захаров В.В. Современные подходы к терапии когнитивных нарушений, не достигающих выраженности деменции. Эффективная фармакотерапия. Неврология и психиатрия. 2013; 1: 56–62. / Zakharov V.V. Sovremennye podkhody k terapii kognitivnykh narushenii, ne dostigaiushchikh vyrazhennosti dementsii. Effektivnaia farmakoterapiia. Nevrologiia i psikhiatriia. 2013; 1: 56–62. [in Russian]
5. Яхно Н.Н., Захаров В.В., Локшина А.Б. и др. Деменции: руководство для врачей. 4-е изд. М.: МЕДпресс-информ, 2013. / Yakhno N.N., Zakharov V.V., Lokshina A.B. i dr. Dementsii: rukovodstvo dlia vrachei. 4-e izd. M.: MEDpress-inform, 2013. [in Russian]
6. Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7 (3): 270–9.
7. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia – meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009; 119 (4): 252–65.
8. Cooper C, Li R, Lyketsos C, Livingston G. Treatment for mild cognitive impairment: systematic review. Br J Psychiatry 2013; 203 (3): 255–64.
9. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011; 10 (9): 819–28.
10. Smith GE, Bondi MW. Mild Cognitive Impairment and Dementia: Definitions, Diagnosis, and Treatment. Oxford; New York: Oxford University Press, 2013.
11. Volkow N, Wang G, Fowler J et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol 1998; 1: 143–7.
12. Halliday G, Barker R, Rowe D. Non-dopamine lesions in Parkinson’s disease. Oxford University Press, 2011; p. 314.
13. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 2001; 9: 1517–9.
14. Calzi F, Bellasio R, Guiso G et al. Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. Eur J Pharmacol 1997; 5 (338): 185–90.
15. Захаров В.В., Локшина А.Б. Применение препарата Проноран (пирибедил) при легких когнитивных расстройствах у пожилых больных с дисциркуляторной энцефалопатией. Неврол. журн. 2004; 2: 30–5. / Zakharov V.V., Lokshina A.B. Primenenie preparata Pronoran (piribedil) pri legkikh kognitivnykh rasstroistvakh u pozhilykh bol'nykh s distsirkuliatornoi entsefalopatiei. Nevrol. zhurn. 2004; 2: 30–5. [in Russian]
16. Brocco M, Dekeyne A, Papp M, Millan MJ. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav Pharmacol 2006; 17 (7): 559–72.
17. Schrag A, Sauerbier A, Chaudhuri KR. New clinical trials for nonmotor manifestations of Parkinson’s disease. Mov Disord. 2015; 30 (11): 1490–504.
18. Thobois S, Lhommée E, Klinger H et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013; 5 (136): 1568–77.
19. Kahvecioglu U, Özkaynak S, Zadikoglu A et al. Efficacy of piribedil on age – related cognitive decline. Medical J Akdeniz University Cilt XII, Sayi 1–3. 1995.
20. Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil. J Neurol 1992; 239 (Suppl. 1): 13–6.
21. Пилипович А.А. Биоэлектрическая активность головного мозга у пациентов с болезнью Паркинсона. Врач. 2012; 4: 107–12. / Pilipovich A.A. Bioelektricheskaia aktivnost' golovnogo mozga u patsientov s bolezn'iu Parkinsona. Vrach. 2012; 4: 107–12. [in Russian]
22. Corradino et al. Trivastal retard 50 in everyday medical practice. Its value in the treatment of dizziness, tinnitus and memory disorders. Trib Med 1988; 3: 39–42.
23. Corbe C, Arnaud F, Brault Y et al. Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects. J Neurol 1992; 239: 22–7.
24. Lassare P, Coppolani T. National multicenter trial in 6000 patients of trivastal retard, 1 tablet per day, in treatment of cerebral insufficiency. Vie Med 1980; 61: 39–50.
25. Пилипович А.А. Влияние Пронорана на депрессивные расстройства при болезни Паркинсона. Consilium Mediсum. 2012; 9: 62–5. / Pilipovich A.A. Vliianie Pronorana na depressivnye rasstroistva pri bolezni Parkinsona. Consilium Medicum. 2012; 9: 62–5. [in Russian]
26. Федорова Н.В., Ким И.П. Лечение болезни Паркинсона. Журн. неврологии и психиатрии. 2002; 2: 68–75. / Fedorova N.V., Kim I.P. Lechenie bolezni Parkinsona. Zhurn. nevrologii i psikhiatrii. 2002; 2: 68–75. [in Russian]
27. Ziegler M, Rondot P. Activity of piribedil in Parkinson’s diseas: a multicenter study. Presse Med 1999; 28: 1414–8.
28. Артемьев Д.В., Захаров В.В., Левин О.С. и др. Старение и нейродегенеративные расстройства: когнитивные и двигательные нарушения в пожилом возрасте. М., 2005. / Artem'ev D.V., Zakharov V.V., Levin O.S. i dr. Starenie i neirodegenerativnye rasstroistva: kognitivnye i dvigatel'nye narusheniia v pozhilom vozraste. M., 2005. [in Russian]
29. Захаров В.В. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). Неврол. журн. 2006; 11: 27–32. / Zakharov V.V. Vserossiiskaia programma issledovanii epidemiologii i terapii kognitivnykh rasstroistv v pozhilom vozraste (“Prometei”). Nevrol. zhurn. 2006; 11: 27–32. [in Russian]
30. Яхно Н.Н., Захаров В.В. Срачунская Е.Я. и др. Лечение недементных когнитивных нарушений у пациентов с артериальной гипертензией и церебральным атеросклерозом. (По результатам российского мультицентрового исследования ФУЭТЕ). Неврол. журн. 2012; 4: 49–55. / Yakhno N.N., Zakharov V.V. Srachunskaia E.Ya. i dr. Lechenie nedementnykh kognitivnykh narushenii u patsientov s arterial'noi gipertenziei i tserebral'nym aterosklerozom. (Po rezul'tatam rossiiskogo mul'titsentrovogo issledovaniia FUETE). Nevrol. zhurn. 2012; 4: 49–55. [in Russian]
31. Левин О.С., Голубева Л.В. Гетерогенность умеренного когнитивного расстройства: диагностические и терапевтические аспекты. Consilium Medicum. 2006; 8 (2): 106–12. / Levin O.S., Golubeva L.V. Geterogennost' umerennogo kognitivnogo rasstroistva: diagnosticheskie i terapevticheskie aspekty. Consilium Medicum. 2006; 8 (2): 106–12. [in Russian]
32. Ганькина О.А. и др. Влияние пирибедила на умеренные когнитивные нарушения при дисциркуляторной энцефалопатии. Журн. неврологии и психиатрии им. С.С.Корсакова. (Прил. Геронтология). 2014; 6 (2): 61–6. / Gankina O.A. i dr. Vliianie piribedila na umerennye kognitivnye narusheniia pri distsirkuliatornoi entsefalopatii. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. (Pril. Gerontologiia). 2014; 6 (2): 61–6. [in Russian]
________________________________________________
2. Smith G, Chandler M, Locke DE et al. Behavioral Interventions to Prevent or Delay Dementia: Protocol for a Randomized Comparative Effectiveness Study. JMIR Res Protoc 2017; 6 (11): e223.
3. Pilipovich A.A. Moderate cognitive disorders. Consilium Medicum. 2016; 18 (2): 44–9.
4. Zakharov V.V. Sovremennye podkhody k terapii kognitivnykh narushenii, ne dostigaiushchikh vyrazhennosti dementsii. Effektivnaia farmakoterapiia. Nevrologiia i psikhiatriia. 2013; 1: 56–62. [in Russian]
5. Yakhno N.N., Zakharov V.V., Lokshina A.B. i dr. Dementsii: rukovodstvo dlia vrachei. 4-e izd. M.: MEDpress-inform, 2013. [in Russian]
6. Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7 (3): 270–9.
7. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia – meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009; 119 (4): 252–65.
8. Cooper C, Li R, Lyketsos C, Livingston G. Treatment for mild cognitive impairment: systematic review. Br J Psychiatry 2013; 203 (3): 255–64.
9. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011; 10 (9): 819–28.
10. Smith GE, Bondi MW. Mild Cognitive Impairment and Dementia: Definitions, Diagnosis, and Treatment. Oxford; New York: Oxford University Press, 2013.
11. Volkow N, Wang G, Fowler J et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol 1998; 1: 143–7.
12. Halliday G, Barker R, Rowe D. Non-dopamine lesions in Parkinson’s disease. Oxford University Press, 2011; p. 314.
13. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 2001; 9: 1517–9.
14. Calzi F, Bellasio R, Guiso G et al. Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. Eur J Pharmacol 1997; 5 (338): 185–90.
15. Zakharov V.V., Lokshina A.B. Primenenie preparata Pronoran (piribedil) pri legkikh kognitivnykh rasstroistvakh u pozhilykh bol'nykh s distsirkuliatornoi entsefalopatiei. Nevrol. zhurn. 2004; 2: 30–5. [in Russian]
16. Brocco M, Dekeyne A, Papp M, Millan MJ. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav Pharmacol 2006; 17 (7): 559–72.
17. Schrag A, Sauerbier A, Chaudhuri KR. New clinical trials for nonmotor manifestations of Parkinson’s disease. Mov Disord. 2015; 30 (11): 1490–504.
18. Thobois S, Lhommée E, Klinger H et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013; 5 (136): 1568–77.
19. Kahvecioglu U, Özkaynak S, Zadikoglu A et al. Efficacy of piribedil on age – related cognitive decline. Medical J Akdeniz University Cilt XII, Sayi 1–3. 1995.
20. Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil. J Neurol 1992; 239 (Suppl. 1): 13–6.
21. Pilipovich A.A. Bioelektricheskaia aktivnost' golovnogo mozga u patsientov s bolezn'iu Parkinsona. Vrach. 2012; 4: 107–12. [in Russian]
22. Corradino et al. Trivastal retard 50 in everyday medical practice. Its value in the treatment of dizziness, tinnitus and memory disorders. Trib Med 1988; 3: 39–42.
23. Corbe C, Arnaud F, Brault Y et al. Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects. J Neurol 1992; 239: 22–7.
24. Lassare P, Coppolani T. National multicenter trial in 6000 patients of trivastal retard, 1 tablet per day, in treatment of cerebral insufficiency. Vie Med 1980; 61: 39–50.
25. Pilipovich A.A. Vliianie Pronorana na depressivnye rasstroistva pri bolezni Parkinsona. Consilium Medicum. 2012; 9: 62–5. [in Russian]
26. Fedorova N.V., Kim I.P. Lechenie bolezni Parkinsona. Zhurn. nevrologii i psikhiatrii. 2002; 2: 68–75. [in Russian]
27. Ziegler M, Rondot P. Activity of piribedil in Parkinson’s diseas: a multicenter study. Presse Med 1999; 28: 1414–8.
28. Artem'ev D.V., Zakharov V.V., Levin O.S. i dr. Starenie i neirodegenerativnye rasstroistva: kognitivnye i dvigatel'nye narusheniia v pozhilom vozraste. M., 2005. [in Russian]
29. Zakharov V.V. Vserossiiskaia programma issledovanii epidemiologii i terapii kognitivnykh rasstroistv v pozhilom vozraste (“Prometei”). Nevrol. zhurn. 2006; 11: 27–32. [in Russian]
30. Yakhno N.N., Zakharov V.V. Srachunskaia E.Ya. i dr. Lechenie nedementnykh kognitivnykh narushenii u patsientov s arterial'noi gipertenziei i tserebral'nym aterosklerozom. (Po rezul'tatam rossiiskogo mul'titsentrovogo issledovaniia FUETE). Nevrol. zhurn. 2012; 4: 49–55. [in Russian]
31. Levin O.S., Golubeva L.V. Geterogennost' umerennogo kognitivnogo rasstroistva: diagnosticheskie i terapevticheskie aspekty. Consilium Medicum. 2006; 8 (2): 106–12. [in Russian]
32. Gankina O.A. i dr. Vliianie piribedila na umerennye kognitivnye narusheniia pri distsirkuliatornoi entsefalopatii. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. (Pril. Gerontologiia). 2014; 6 (2): 61–6. [in Russian]
Авторы
А.А.Пилипович
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
aapilipovich@mail.ru
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
aapilipovich@mail.ru
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
aapilipovich@mail.ru
________________________________________________
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
aapilipovich@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.